We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03744468
Recruitment Status : Recruiting
First Posted : November 16, 2018
Last Update Posted : November 29, 2022
Sponsor:
Information provided by (Responsible Party):
BeiGene

Brief Summary:
This is an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of BGB-A425 and/or LBL-007 with tislelizumab.

Condition or disease Intervention/treatment Phase
Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2 Drug: BGB-A425 Drug: Tislelizumab Drug: LBL-007 Phase 1 Phase 2

Detailed Description:

Blocking antibodies targeting PD-1 have achieved remarkable results in the treatment of many types of tumors. However, based upon the rate of primary and secondary resistance to PD-1 blockade, it is apparent that additional immuno-regulatory mechanism(s) underlie tumor immune escape. Indeed, research shows that the TIM-3 pathway cooperates with PD-1 to maximize the suppression of effector TILs as well as promote resistance to anti-PD-1 therapy. Therefore, TIM-3 represents an ideal target with the potential to significantly improve and/or extend the therapeutic benefit of anti-PD-1 therapy to a greater number of patients.

TIM3, LAG3, and PD-1 function as immune checkpoint receptors in the overlapping regulation of immune tolerance and have been shown to be co-overexpressed on the tumor infiltrating lymphocytes (TILs) from the participant samples of various solid tumors. Furthermore, emerging clinical data and preclinical data demonstrate co-expression of Tim-3, LAG-3, PD-1 often yield T cells' exhausted immunophenotype (ie, cytokine expression, proliferation etc.). Cancer cells take advantage of PD-1, TIM-3, and LAG-3 in inhibiting immune cells' function, and escape the immune surveillance. Based upon the overlapping expression profiles and immuno-regulatory functions, TIM-3 and LAG-3 mediated adaptive resistance, there is strong scientific rationale that simultaneous targeting of these checkpoint blockers, could potentially increase therapeutic benefit and may help to overcome the resistance arising due to anti-PD-(L)-1 therapy. Hence, this study will evaluate the safety and preliminary efficacy of BGB-A425 (anti TIM-3), LBL-007 (Anti-LAG-3) in combination with tislelizumab (anti PD-1) in patients with advanced solid tumors

This is an open-label, multicenter, nonrandomized Phase 1 and Phase 2 clinical trial. Phase 1 will determine the recommended phase 2 dose (RP2D) for the combination of BGB-A425 and Tislelizumab. Phase 2 safety lead-in will determine the RP2D for the combination of BGB-A425, Tislelizumab and/or LBL-007. Phase 2 dose expansion will continue to evaluate the safety but also focus on the efficacy of the doublet or triplet treatment combination in select tumor types.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 358 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This is an open-label, multicenter, nonrandomized Phase 1 and Phase 2 clinical trial. Phase 1 will determine the recommended phase 2 dose (RP2D) for the combination of BGB-A425 and Tislelizumab. Phase 2 safety lead-in will determine the RP2D for the combination of BGB-A425, Tislelizumab and/or LBL-007. Phase 2 dose expansion will continue to evaluate the safety but also focus on the efficacy of the double or triplet treatment combination in select tumor types.
Masking: None (Open Label)
Masking Description: Open Label
Primary Purpose: Treatment
Official Title: Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 With Tislelizumab in Patients With Advanced Solid Tumors
Actual Study Start Date : November 13, 2018
Estimated Primary Completion Date : March 31, 2026
Estimated Study Completion Date : December 29, 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Safety

Arm Intervention/treatment
Experimental: Phase 1 Dose Escalation
Dose escalation of BGB-A425 in combination with Tislelizumab in participants with advanced solid tumors
Drug: BGB-A425
Humanized IgG1-variant monoclonal antibody against TIM-3

Drug: Tislelizumab
Humanized, IgG4-variant monoclonal antibody against PD-1
Other Name: BGB-A317

Experimental: Phase 2 Safety Lead-in
Dose escalation for Cohort A (LBL-007 + Tislelizumab) and Cohort B (BGB-A425 + LBL-007 + Tislelizumab) in participants with advanced solid tumors
Drug: BGB-A425
Humanized IgG1-variant monoclonal antibody against TIM-3

Drug: Tislelizumab
Humanized, IgG4-variant monoclonal antibody against PD-1
Other Name: BGB-A317

Drug: LBL-007
Human anti LAG-3 IgG4-kappa antibody

Experimental: Phase 2 Dose Expansion
Further explore the safety and clinical activity of BGB-A425 and LBL-007 in combination with Tislelizumab in participants with NSCLC, HNSCC and RCC
Drug: BGB-A425
Humanized IgG1-variant monoclonal antibody against TIM-3

Drug: Tislelizumab
Humanized, IgG4-variant monoclonal antibody against PD-1
Other Name: BGB-A317

Drug: LBL-007
Human anti LAG-3 IgG4-kappa antibody




Primary Outcome Measures :
  1. Phase 1 Dose Escalation and Phase 2 Safety lead-in: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [ Time Frame: Approximately 2 years ]

    A TEAE is defined as an AE that had an onset date or a worsening in severity from baseline (pretreatment) on or after the first dose of study drug up to 30 days following study drug discontinuation or initiation of new anticancer therapy, whichever comes first.

    An SAE is any untoward medical occurrence that at any dose results in death or is life threatening.


  2. Phase 1 Dose Escalation: Maximum Tolerated Dose (MTD) [ Time Frame: Approximately 2 years ]
    The MTD or MAD is defined as the highest dose at which < 33% of the participants experience a dose limiting toxicity (DLT)

  3. Phase 2 Dose Expansion: Objective Response Rate (ORR) [ Time Frame: Approximately 2 years ]
    ORR is determined from the investigator derived tumor assessments per RECIST v1.1


Secondary Outcome Measures :
  1. Phase 1 and Phase 2 : Duration of Response (DOR) [ Time Frame: Phase 1 or 2 Expansion - Approximately 2-3 years each ]
    Duration of response (DOR) will be determined from investigator derived tumor assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1.

  2. Phase 1 and Phase 2 : Disease control rate (DCR) [ Time Frame: Phase 1 or 2 Expansion - Approximately 2-3 years each ]
    Disease control rate (DCR) will be determined from investigator derived tumor assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1.

  3. Phase 1 and Phase 2 : Progression free survival [ Time Frame: Phase 2 Expansion - Approximately 3 years ]
    Progression free survival will be determined from investigator derived tumor assessments per RECIST 1.1.

  4. Pharmacokinetic (PK) Parameter: Minimum Concentration (Cmin) of BGB-425 and LBL-007 [ Time Frame: Phase 1 and Phase 2- Approximately 2-3 years each ]
  5. PK Parameter: Area Under the Curve (AUC), 0 to 21 days of BGB-425 and LBL-007 [ Time Frame: Phase 1 and Phase 2- Approximately 2-3 years each ]
  6. PK Parameter: Maximum Concentration (Cmax) of BGB-425 and LBL-007 [ Time Frame: Phase 1 and Phase 2- Approximately 2-3 years each ]
  7. PK Parameter: Clearance (CL) of BGB-425 and LBL-007 [ Time Frame: Phase 1 and Phase 2- Approximately 2-3 years each ]
  8. PK Parameter: Volume of Distribution (Vz) of BGB-425 and LBL-007 [ Time Frame: Phase 1 and Phase 2- Approximately 2-3 years each ]
  9. PK Parameter: terminal half-life (t1/2) of BGB-425 and LBL-007 [ Time Frame: Phase 1 and Phase 2- Approximately 2-3 years each ]
  10. Percentage of participants with anti-BGB-A425 and LBL-007 antibodies [ Time Frame: Phase 1 and Phase 2- Approximately 2-3 years each ]
  11. Phase 2 Dose Expansion: Number of participants with TEAEs and SAEs including physical examinations, electrocardiograms and laboratory assessments [ Time Frame: Phase 1 and Phase 2- Approximately 2-3 years each ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

Has Eastern Cooperative Oncology Group (ECOG) Performance Status ≤1.

  • Adequate organ function
  • Phase 1 Dose Escalation + Phase 2 Safety Lead-In: Participants with histologically or cytologically confirmed advanced, metastatic, unresectable solid tumors who have previously received standard systemic therapy or for which treatment is not available, not tolerated or refused.
  • Phase 2 Dose-Expansion: Participants with one of the following histologically or cytologically confirmed solid tumors:
  • For HNSCC participants in cohort 1,4 and 6 (PD-L1 positive):

Recurrent/metastatic head and neck squamous cell cancer of the oral cavity, oropharynx, hypopharynx, and/or larynx whose tumor is not amenable to local therapy with curative intent (ie, surgery or radiation therapy with or without chemotherapy • For NSCLC participants in Cohort 2, 5 and 7 (PD-L1 positive): Locally recurrent Stage IIIB, stage IIIC or Stage IV squamous or non-squamous non-small cell lung cancer

• For RCC participants in Cohort 3: Locally advanced unresectable or metastatic and histologically confirmed renal cell carcinoma with a clear cell histology

Key Exclusion Criteria:

  • NSCLC patients with known EGFR mutation, BRAF mutation, ALK fusion, or ROS1 fusion
  • Active leptomeningeal disease or uncontrolled, untreated brain metastasis.
  • Active autoimmune diseases or history of autoimmune diseases that may relapse.
  • Interstitial lung disease, noninfectious pneumonitis or uncontrolled lung diseases
  • Uncontrolled diabetes or significant cardiac issues
  • Infections requiring systemic antibacterial, antifungal, or antiviral therapy
  • History of severe hypersensitivity reactions to other monoclonal antibodies
  • History of HIV infection or untreated chronic hepatitis B or chronic hepatitis B virus carriers
  • Major surgical procedure within 28 days before study drug administration
  • Chemotherapy, radiotherapy, immunotherapy or any investigational therapies within 28 days (PH 2 Safety Lead-In) or 14 days (PH 2 Dose Expansion) or 5 half-lives of (whichever is shorter) of first administration of study drug(s).
  • With infections (including tuberculosis infection, etc) requiring systemic antibacterial, antifungal, or antiviral therapy ≤ 14 days prior to the first dose of study drug(s), or a requirement for chronic prophylactic treatment with antibiotics.
  • Concurrent participation in another therapeutic clinical trial
  • Received prior therapies targeting TIM-3and/or LAG3

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03744468


Contacts
Layout table for location contacts
Contact: BeiGene 1 (877) 828-5568 clinicaltrials@beigene.com

Locations
Show Show 39 study locations
Sponsors and Collaborators
BeiGene
Investigators
Layout table for investigator information
Study Director: Hua-Xin Gao BeiGene
Layout table for additonal information
Responsible Party: BeiGene
ClinicalTrials.gov Identifier: NCT03744468    
Other Study ID Numbers: BGB-900-102
U1111-1278-0027 ( Other Identifier: UTN Number )
First Posted: November 16, 2018    Key Record Dates
Last Update Posted: November 29, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms